Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Association of Profylactic Use of Stress Ulcus Drugs och kliniska resultat hos patienter med akut främre cirkulationstrombektomi

2 november 2026 uppdaterad av: Nanfang Hospital, Southern Medical University

Association of Profylactic Use of Stress Ulcus Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombeectomy: a Prospective, Multicenter, Observational Cohort Study

Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.

However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Studietyp

Observationell

Inskrivning (Beräknad)

2592

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Fujian
      • Fuzhou, Fujian, Kina
        • Rekrytering
        • Fujian Medical University Union Hospital
        • Kontakt:
          • Shenggen Chen, M.D.
          • Telefonnummer: 13459480275
    • Guangdong
      • Dongguan, Guangdong, Kina
        • Rekrytering
        • Dongguan People's Hospital
        • Kontakt:
          • Zhu Shi, M.D.
          • Telefonnummer: 13669825459
      • Dongguan, Guangdong, Kina
        • Rekrytering
        • Dongguan donghua hospital
        • Kontakt:
          • Lingyu Sun
          • Telefonnummer: 13829203368
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • Nanfang Hospital of Southern Medical University
        • Kontakt:
          • Suyue Pan
          • Telefonnummer: 13556184981
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • Guangdong Provincial Hospital of Traditional Chinese Medicine
        • Kontakt:
          • Lixin Wang, M.D.
          • Telefonnummer: 13922793886
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • Huadu District People's Hospital of Guangzhou
        • Kontakt:
          • Guangning Li, M.D.
          • Telefonnummer: 13926239656
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • The Fourth Affiliated Hospital of Guangzhou Medical University
        • Kontakt:
          • Wangchi Luo, M.D.
          • Telefonnummer: 13710895142
      • Heyuan, Guangdong, Kina
        • Rekrytering
        • Heyuan people's Hospital
        • Kontakt:
          • Minzhen Zhu
          • Telefonnummer: 15007622318
      • Huizhou, Guangdong, Kina
        • Rekrytering
        • Huizhou Municipal Central Hospital
        • Kontakt:
          • Lizhi Wang, M.D.
          • Telefonnummer: 13802872076
    • Hainan
      • Haikou, Hainan, Kina
        • Rekrytering
        • Hainan Provincial People's Hospital
        • Kontakt:
          • Fan Zhang, M.D.
          • Telefonnummer: 17389897580
      • Haikou, Hainan, Kina
        • Rekrytering
        • Haikou People's Hospital
        • Kontakt:
          • Guoshuai Yang, M.D.
          • Telefonnummer: 13876006248
      • Haikou, Hainan, Kina
        • Rekrytering
        • Hainan Traditional Chinese Medicine Hospital
        • Kontakt:
          • Yong Gu, M.D.
          • Telefonnummer: 15521280288
    • Hunan
      • Changsha, Hunan, Kina
        • Rekrytering
        • The First Hospital of Changsha
        • Kontakt:
          • Xu Peng, M.D。
          • Telefonnummer: 15802507292
      • Hengyang, Hunan, Kina
        • Rekrytering
        • The Second Hospital University of South China
        • Kontakt:
          • Yanhong Hu, M.D.
          • Telefonnummer: 13265004191
      • Yueyang, Hunan, Kina
        • Rekrytering
        • Yueyang People's Hospital
        • Kontakt:
          • Yuan Zhou, M.D.
          • Telefonnummer: 15107309796
    • Inner Mongolia
      • Baotou, Inner Mongolia, Kina
        • Rekrytering
        • Sinopharm North Hospital
        • Kontakt:
          • Lifei Xing, M.D
          • Telefonnummer: 15354919958
      • Hohhot, Inner Mongolia, Kina
        • Rekrytering
        • The Affiliated Hospital of Inner Mongolia Medical University
        • Kontakt:
          • Lihua Sun, M.D.
          • Telefonnummer: 18686292585
    • Jiangxi
      • Ganzhou, Jiangxi, Kina
        • Rekrytering
        • Ganzhou City People's Hospital
        • Kontakt:
          • Zhaohui Lai
          • Telefonnummer: 13879729792
    • Zhejiang
      • Wenzhou, Zhejiang, Kina
        • Rekrytering
        • Second Affiliated Hospital of Wenzhou Medical University
        • Kontakt:
          • Saijun Zhou, M.D.
          • Telefonnummer: 13857746659

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.

Beskrivning

Inclusion Criteria:

  1. Age ≥18 years.
  2. Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the "China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018".
  3. Meet the indications for mechanical thrombectomy in the "Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022".
  4. Treated with mechanical thrombectomy.
  5. NIHSS score ≥ 6 at onset of illness.
  6. Sign an informed notice.

Exclusion Criteria:

Allergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.

Have participated in other interventional clinical studies (affecting the outcome of this cohort study).

Participants who were judged by the investigator to be unsuitable for participation in this study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Stress Ulcer Prophylaxis

Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.

Control Group

Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
90-day mortality after onset
Tidsram: 90-day after onset

Proportion of enrolled patients who died 90 days after onset of disease.

90-day after onset
Incidence of stroke-associated pneumonia
Tidsram: within 7-day of onset

Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset

within 7-day of onset

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of clinically significant bleeding
Tidsram: within 7-day of onset

One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U.

within 7-day of onset
Incidence of stress ulcer bleeding
Tidsram: 7-day after onset

Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood

7-day after onset
Incidence of unfavorable functional prognosis at 90 days after onset
Tidsram: 90-day after onset

Incidence of unfavorable functional prognosis at 90 days after onset

90-day after onset
90-day mRS score change
Tidsram: 90-day after onset

Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria

90-day after onset
Incidence of early neurological deterioration
Tidsram: within 72 hours after onset

Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4

within 72 hours after onset
1-year post-onset mortality
Tidsram: 1 year after onset

Mortality at 1 year after onset in patients who were eligible for inclusion criteria

1 year after onset
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset
Tidsram: 1 year after onset

Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria

1 year after onset

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 maj 2023

Primärt slutförande (Faktisk)

1 augusti 2026

Avslutad studie (Beräknad)

1 maj 2027

Studieregistreringsdatum

Först inskickad

26 april 2023

Först inskickad som uppfyllde QC-kriterierna

26 april 2023

Första postat (Faktisk)

6 maj 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera